Key Highlights

  • NRx Pharmaceuticals (NASDAQ:NRXP) reported a third-quarter net loss of USD 2.2 million, or USD 0.05 per share, against USD 5.9 million, or USD 0.27 per share, a year earlier.
  • The loss from operations roughly doubled to USD 8.1 million from USD 4.0 million as selling, general and administrative expense rose to USD 6.6 million.
  • A USD 6.2 million gain on the Fair Value of Warrant liabilities offset the operating loss in the quarter.
  • Cash and cash equivalents were USD 19.8 million at September 30, 2026, with a Working Capital Deficit of USD 7.0 million.

A Warrant Gain Masks a Doubling of the Operating Loss

NRx Pharmaceuticals (NASDAQ:NRXP) filed its Quarterly Report on November 16, 2026, showing a third-quarter net loss of USD 2.2 million. The headline improvement comes from other income: a USD 6.2 million gain on the change in fair value of warrant liabilities, compared with a USD 5.0 million charge in the prior year quarter. This is a non-cash accounting item that moves with the share price.

The loss from operations was USD 8.1 million against USD 4.0 million, as total operating expenses climbed to USD 9.3 million from USD 4.3 million. Selling, general and administrative expense rose to USD 6.6 million from USD 2.8 million, while Research and Development edged up to USD 1.8 million from USD 1.4 million.

Clinic Revenue Builds After the Dura Acquisition

The company develops pharmaceutical candidates for central nervous system conditions, led by NRX-100 and NRX-101, and also operates interventional psychiatry clinics through its HOPE subsidiary. Net patient service revenue was USD 1.2 million in the quarter, up from USD 0.2 million, and USD 3.3 million over nine months, following the Acquisition of Dura on September 8, 2025.

Cost of patient services was USD 874 thousand in the quarter. Nine-month net loss narrowed to USD 20.1 million, or USD 0.53 per share, from USD 29.0 million, or USD 1.54 per share, a year earlier.

In May 2026 the company was told by Swiss authorities that it had won the Liquidation sale of GeNeuro assets, a package of patents, antibodies and data from three completed human trials. Manufacturing of an anti HERV-K antibody has begun for a planned first in human ALS trial targeted for July 2027.

Cash Rises to USD 19.8 Million but Going Concern Doubt Remains

Cash and cash equivalents grew to USD 19.8 million from USD 7.8 million at year-end 2025. Financing activities provided USD 32.8 million over nine months, including about USD 11.8 million of net proceeds from the at-the-market program, while Operating Activities used USD 19.9 million.

The filing still states that substantial doubt exists about the company continuing as a going concern for twelve months. Current liabilities of USD 29.2 million include USD 12.3 million of warrant liabilities, leaving a working capital deficit of USD 7.0 million and a stockholders deficit of USD 2.0 million. Shares outstanding rose to 43,207,744 from 31,734,333 at year-end.

Where Things Stand

The lower net loss reflects accounting gains, not lower spending. NRx Pharmaceuticals (NASDAQ:NRXP) saw its operating loss double to USD 8.1 million, yet cash rose to USD 19.8 million on financing. Calculated from the filing, nine-month operating cash use of USD 19.9 million equals about USD 2.2 million a month, so the cash balance covers roughly nine months at that pace. Regulatory decisions on NRX-100 and NRX-101, clinic revenue growth and further use of the at-the-market program are the items the filing points to.